HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AESGP Conference Round-Up: Digital Disruption, Med Device Worries And The Benefits Of Switching

Executive Summary

Speakers from the EMA and European Commission, as well as Pfizer and HRA Pharma, debated at the AESGP's Regulatory Conference the ongoing digital transformation of the European consumer healthcare market, the latest developments in the implementation of the new medical devices regulations, and the best ways to encourage Rx-to-OTC switching across the EU.

You may also be interested in...

AESGP Annual Meeting Cancelled Due To Coronavirus Concerns

The exponential spread of Covid-19 across Europe has forced the European industry association, the AESGP, to make the difficult decision of cancelling its annual meeting this May.

Self-Care Medical Devices Sitting In The ‘Danger Zone,’ AESGP Warns

The Association of the European Self-Medication Industry (AESGP) warns that many self-care medical devices could fall through the cracks of implementing new EU regulations, as the deadline draws near. 

How Pfizer Achieved 'Switch Success' With Viagra and Nexium

Pfizer secured two of the biggest prescription-to-OTC switches in recent years with the reclassification of Viagra and Nexium. Michelle Riddalls, Pfizer's director of regulatory affairs in Europe, offers her advice to firms looking to emulate this 'switch success'.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts